95333-95-2Relevant articles and documents
BENZENE FUSED HETEROCYCLIC COMPOUND AND USE THEREOF
-
Paragraph 0280; 0380; 0383; 0384, (2019/06/17)
The present disclosure provides a benzene fused heterocyclic compound of Formula (I): wherein (A) is a single or double bond; n is 0 or 1; X is -CH2-, O, NR1, or S; A is -C(Ra1)(Ra2)(Ra3) or -N(R
Indanylidenes. 2. Design and synthesis of (E)-2-(4-chloro-6-fluoro-1-indanylidene)-N-methylacetamide, a potent antiinflammatory and analgesic agent without centrally acting muscle relaxant activity
Musso, David L.,Orr, G. Faye,Cochran, Felicia R.,Kelley, James L.,Selph, Jeffrey L.,Rigdon, Greg C.,Cooper, Barrett R.,Jones, Michael L.
, p. 409 - 416 (2007/10/03)
Extension of the structure-activity relationship studies that led to the discovery of the nonsedating potent muscle relaxant, antiinflammatory, and analgesic agent (E)-2-(4,6-difluoro-1-indanylidene)acetamide, 1, has given rise to (E)-2-(4-chloro-6-fluoro
Prevention of loss and restoration of bone mass by certain prostaglandin agonists
-
, (2008/06/13)
Prostaglandin agonists of formula (I), in which, for example, A is a sulphonyl or acyl group, B is N or CH, M contains a ring and K and Q are linking groups, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits useful for the treatment of bone disorders including osteoporosis. STR1
